Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation. / Tram Henriksen, Louise; Gottschalk Højfeldt, Sofie; Schmiegelow, Kjeld; Frandsen, Thomas Leth; Skov Wehner, Peder; Schrøder, Henrik; Klug Albertsen, Birgitte; Nordic Society of Pediatric Hematology and Oncology, NOPHO Group.

I: Pediatric Blood & Cancer, Bind 64, Nr. 12, e26686, 12.2017.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Tram Henriksen, L, Gottschalk Højfeldt, S, Schmiegelow, K, Frandsen, TL, Skov Wehner, P, Schrøder, H, Klug Albertsen, B & Nordic Society of Pediatric Hematology and Oncology, NOPHO Group 2017, 'Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation', Pediatric Blood & Cancer, bind 64, nr. 12, e26686. https://doi.org/10.1002/pbc.26686

APA

Tram Henriksen, L., Gottschalk Højfeldt, S., Schmiegelow, K., Frandsen, T. L., Skov Wehner, P., Schrøder, H., Klug Albertsen, B., & Nordic Society of Pediatric Hematology and Oncology, NOPHO Group (2017). Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation. Pediatric Blood & Cancer, 64(12), [e26686]. https://doi.org/10.1002/pbc.26686

Vancouver

Tram Henriksen L, Gottschalk Højfeldt S, Schmiegelow K, Frandsen TL, Skov Wehner P, Schrøder H o.a. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation. Pediatric Blood & Cancer. 2017 dec.;64(12). e26686. https://doi.org/10.1002/pbc.26686

Author

Tram Henriksen, Louise ; Gottschalk Højfeldt, Sofie ; Schmiegelow, Kjeld ; Frandsen, Thomas Leth ; Skov Wehner, Peder ; Schrøder, Henrik ; Klug Albertsen, Birgitte ; Nordic Society of Pediatric Hematology and Oncology, NOPHO Group. / Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation. I: Pediatric Blood & Cancer. 2017 ; Bind 64, Nr. 12.

Bibtex

@article{958bb15f835842f7b39d13c60310c27b,

title = "Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation",

abstract = "BACKGROUND: As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.METHODS: The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG-asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l-asparaginase activity and formation of anti-PEG-asparaginase antibodies. A total of 97 evaluable patients (1-17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG-asparaginase (Oncaspar({\textregistered}) ) 1,000 IU/m²/dose, at 2-week or 6-week intervals with a total of 30-week treatment (Clinical trials.gov. no.: NCT00819351).RESULTS: The pharmacological target of treatment (l-asparaginase activity above 100 IU/l) was reached in 612 of 652 (94%) samples obtained 14 ± 2 days after PEG-asparaginase administration. Mean l-asparaginase activity was 338 IU/l. Six patients had l-asparaginase activity below 50 IU/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti-PEG-asparaginase antibodies, but there was no correlation between anti-PEG-asparaginase antibodies and low levels of asparaginase activity.CONCLUSION: We conclude that prolonged first-line biweekly PEG-asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti-PEG-asparaginase antibodies was not a predictor of l-asparaginase activity.",

keywords = "Adolescent, Antibodies, Antineoplastic Agents, Asparaginase, Child, Child, Preschool, Female, Humans, Infant, Male, Polyethylene Glycols, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Journal Article, Randomized Controlled Trial",

author = "{Tram Henriksen}, Louise and {Gottschalk H{\o}jfeldt}, Sofie and Kjeld Schmiegelow and Frandsen, {Thomas Leth} and {Skov Wehner}, Peder and Henrik Schr{\o}der and {Klug Albertsen}, Birgitte and {Nordic Society of Pediatric Hematology and Oncology, NOPHO Group}",

note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = dec,

doi = "10.1002/pbc.26686",

language = "English",

volume = "64",

journal = "Pediatric Blood & Cancer",

issn = "1545-5009",

publisher = "JohnWiley & Sons, Inc.",

number = "12",

}

RIS

TY - JOUR

T1 - Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation

AU - Tram Henriksen, Louise

AU - Gottschalk Højfeldt, Sofie

AU - Schmiegelow, Kjeld

AU - Frandsen, Thomas Leth

AU - Skov Wehner, Peder

AU - Schrøder, Henrik

AU - Klug Albertsen, Birgitte

AU - Nordic Society of Pediatric Hematology and Oncology, NOPHO Group

PY - 2017/12

Y1 - 2017/12

N2 - BACKGROUND: As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.METHODS: The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG-asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l-asparaginase activity and formation of anti-PEG-asparaginase antibodies. A total of 97 evaluable patients (1-17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG-asparaginase (Oncaspar(®) ) 1,000 IU/m²/dose, at 2-week or 6-week intervals with a total of 30-week treatment (Clinical trials.gov. no.: NCT00819351).RESULTS: The pharmacological target of treatment (l-asparaginase activity above 100 IU/l) was reached in 612 of 652 (94%) samples obtained 14 ± 2 days after PEG-asparaginase administration. Mean l-asparaginase activity was 338 IU/l. Six patients had l-asparaginase activity below 50 IU/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti-PEG-asparaginase antibodies, but there was no correlation between anti-PEG-asparaginase antibodies and low levels of asparaginase activity.CONCLUSION: We conclude that prolonged first-line biweekly PEG-asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti-PEG-asparaginase antibodies was not a predictor of l-asparaginase activity.

AB - BACKGROUND: As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.METHODS: The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG-asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l-asparaginase activity and formation of anti-PEG-asparaginase antibodies. A total of 97 evaluable patients (1-17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG-asparaginase (Oncaspar(®) ) 1,000 IU/m²/dose, at 2-week or 6-week intervals with a total of 30-week treatment (Clinical trials.gov. no.: NCT00819351).RESULTS: The pharmacological target of treatment (l-asparaginase activity above 100 IU/l) was reached in 612 of 652 (94%) samples obtained 14 ± 2 days after PEG-asparaginase administration. Mean l-asparaginase activity was 338 IU/l. Six patients had l-asparaginase activity below 50 IU/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti-PEG-asparaginase antibodies, but there was no correlation between anti-PEG-asparaginase antibodies and low levels of asparaginase activity.CONCLUSION: We conclude that prolonged first-line biweekly PEG-asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti-PEG-asparaginase antibodies was not a predictor of l-asparaginase activity.

KW - Adolescent

KW - Antibodies

KW - Antineoplastic Agents

KW - Asparaginase

KW - Child

KW - Child, Preschool

KW - Female

KW - Humans

KW - Infant

KW - Male

KW - Polyethylene Glycols

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1002/pbc.26686

DO - 10.1002/pbc.26686

M3 - Journal article

C2 - 28660740

VL - 64

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

SN - 1545-5009

IS - 12

M1 - e26686

ER -

ID: 185028850